Tyra Biosciences, Inc.
TYRA
Jodie situation report
Tyra Biosciences, Inc.'s move is being confirmed by its market group.
TYRA accounts for 4.6% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
PRAX, RCUS, MAZE moved materially before TYRA. TYRA crossed its material path threshold at 15:05 ET, 1395 minutes after the first measured mover.
10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 3 disclosed connections are confirming.
- At least 11 of 16 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NBIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.
Who this business touches
The relationships behind TYRA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
BBIOBridgeBio Pharma, Inc.competitorFeb 24, 2026 ▾
“Other companies are developing therapies for achondroplasia, including Ascendis Pharma A/S (TransCon CNP), Tyra Biosciences, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TYRA is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.